United Therapeutics CEO trusts sell 9,500 shares
The pre-arranged trading plan continues until the earlier of exercise of 1,734,410 options, all expiring March 15, 2027, or December 31, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
United Therapeutics Corp. Chairperson & CEO Martine A. Rothblatt reported that a family trust exercised 9,500 stock options on October 29, 2026, at $117.76 per share, acquiring 9,500 common shares; family trusts also sold 9,500 common shares that day under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025. The sale entries report per-share prices of $590.4296 (53 shares), $591.9020 (1,104), $592.9686 (1,563), $593.8794 (1,540), $594.8947 (1,248), $595.8794 (1,678), $596.8608 (1,355), $597.6552 (919), and $599.30 (40). For multiple-trade batches with price footnotes, the reported prices are weighted averages. The option position after the exercise was 128,910 options.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F1, F14, F15 | 9,500 | $0.00 | $0.00 |
| Exercise | Common Stock F1, F2 | 9,500 | $117.76 | $1.12M |
| Sale | Common Stock F1, F3, F2 | 53 | $590.4296 | $31K |
| Sale | Common Stock F1, F4, F2 | 1,104 | $591.902 | $653K |
| Sale | Common Stock F1, F5, F2 | 1,563 | $592.9686 | $927K |
| Sale | Common Stock F1, F6, F2 | 1,540 | $593.8794 | $915K |
| Sale | Common Stock F1, F7, F2 | 1,248 | $594.8947 | $742K |
| Sale | Common Stock F1, F8, F2 | 1,678 | $595.8794 | $1000K |
| Sale | Common Stock F1, F9, F2 | 1,355 | $596.8608 | $809K |
| Sale | Common Stock F1, F10, F2 | 919 | $597.6552 | $549K |
| Sale | Common Stock F1, F2 | 40 | $599.30 | $24K |
| Holding | Common Stock | -- | -- | -- |
| Holding | Common Stock | -- | -- | -- |
| Holding | Common Stock F11 | -- | -- | -- |
| Holding | Common Stock F12 | -- | -- | -- |
| Holding | Common Stock F13 | -- | -- | -- |
Footnotes (15)
- F1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
- F10. This transaction was executed in multiple trades at prices ranging from $597.41 to $598.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F11. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F12. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F13. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F14. These stock options vested in equal one-third installments on March 15, 2021, 2022 and 2023.
- F15. Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
- F2. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F3. This transaction was executed in multiple trades at prices ranging from $590.17 to $590.52. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $591.33 to $592.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $592.36 to $593.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $593.39 to $594.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $594.41 to $595.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $595.41 to $596.38. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. This transaction was executed in multiple trades at prices ranging from $596.41 to $597.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Key Terms
pre-arranged 10b5-1 trading plan regulatory
weighted average price financial
investment power regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When does the UTHR Rule 10b5-1 plan end?
AI-generated analysis. How Rhea-AI works. Not financial advice.